ÌìÃÀÓ°Ôº

A reversible liver condition is the fastest growing cause of liver transplantation in Western countries: Metabolic dysfunction-associated steatotic liver disease, or MASLD, affects patients worldwide. It’s characterized by excessive fat accumulation in the liver and can progress into more severe forms of liver disease, potentially resulting in fibrosis, cirrhosis and liver failure.

In this episode, experts in the field of liver disease address the progress happening in the recognition, diagnosis and treatment of the disease. 

Host Matt Gee, Director of collaborations and external engagement at Siemens Healthineers, is joined by:

• Dr. Michelle Long, International Medical Vice President of Metabolic Dysfunction-Associated Steatohepatitis at Novo Nordisk and Director of Clinical Research for the Section of Gastroenterology and Hepatology at Boston University 
• Dr. Arun Sanyal, Professor of Medicine, Physiology, and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University 
• Michael Betel, President and Founder of the Fatty Liver Alliance